Ella Fitszimmons
Sep 10, 2008

Xian Janssen shifts two brands to Bates141

BEIJING - Bates141 has secured the creative duties for two of Johnson & Johnson subsidiary Xian Janssen Pharmaceutical's over-the-counter products, following a pitch contested by two other agencies.

Xian Janssen shifts two brands to Bates141
DMG was the incumbent for Motilium, which has a reported media spend of US$30 million, though it could not be confirmed whether it attempted to defend the account.

Motilium (a stomach motility drug) is currently the most successful OTC medication across categories in China. The second brand, Mylanta, is a new antacid.

Source:
Campaign China

Related Articles

Just Published

2 days ago

AI, copyright, and creativity: The fine line ...

With tech giants lobbying for AI training on copyrighted material and artists filing lawsuits to protect their work, adland faces the challenge of integrating AI while respecting copyright, originality, and the livelihoods of creators.

2 days ago

Women to Watch 2024: Vivian Liu, DeVries Global

A PR veteran, Liu empowers the next generation in Taiwan by promoting fairness, authenticity, and industry excellence.

2 days ago

A new campaign gives dignity to Vietnam's unsung heroes

This Labour Day, a powerful tribute by creative agency The Friday urges us to see the workers we pass by without a second thought. But does recognition go far enough?

2 days ago

Amazon unveils first brand overhaul in 25 years, ...

The subtle design refresh spans over 50 sub-brands across categories like pharmacy, groceries, and on-demand streaming under a single brand umbrella.